Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04159896 · ClinicalTrials.gov registry record · Phase 2
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04159896 is a Phase 2 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT04159896, a Phase 2 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic). ESK981 is an investigational drug that targets several important pathways that are believed to play a role in the spread of cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if giving ESK981 and nivolumab together works better in treating metastatic castration resistant prostate cancer compared to usual treatments.
Interventions
- BIOLOGICAL Nivolumab
- DRUG Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04159896
The ClinicalTrials.gov registry entry for NCT04159896 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04159896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04159896 about?
NCT04159896 is a clinical study titled "ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer". This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic). ESK981 is an investigational drug that targets several important pathways that are be...
What is the current status of trial NCT04159896?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-11-13. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04159896?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981 (DRUG).
Who is sponsoring clinical trial NCT04159896?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.